Anavar 25 mg 100 Tablets Hutech Labs USA

Product Overview

Hutech Labs USA’s Anavar 25 mg presents oxandrolone, the C2-oxa DHT derivative anabolic steroid, in scored white tablets exhibiting pharmaceutical-grade specifications (molecular weight 306.44) for institutional performance catalogs. The 100-tablet tamper-evident configuration supports CIII-compliant inventory management across encrypted specialist platforms requiring precise potency declaration and batch traceability.

U.S. domestic manufacturing eliminates customs exposure while maintaining USP-equivalent morphology distinguishing legitimate Schedule III supply from underground conversions prevalent in non-verified markets. This intermediate dosage serves advanced resellers managing structured DEA-regulated workflows rather than pharmaceutical or recreational crossover.

Anavar 25 mg targets verified CIII ecosystems emphasizing commercial positioning without protocols, cycles, or therapeutic claims.​

Brand & Manufacturer Information

Hutech Labs USA produces Schedule III anabolics through domestic facilities serving institutional performance distribution requiring controlled substance compliance. The 25 mg/100-tab specification maintains catalog continuity alongside Hutech high-potency orals while authenticating legitimate institutional product versus powder-pressed alternatives.​

Domestic warehousing supports DEA Form 222 record-keeping across encrypted platforms confirming oxandrolone identity/potency.

Active Compound Information

Contains oxandrolone (17β-hydroxy-17α-methyl-2-oxa-5α-androstan-3-one) featuring high anabolic:androgenic dissociation (~10:1) characteristic of 17α-alkylated C2-oxa steroids enabling oral bioavailability without aromatization. DEA Schedule III (21 CFR 1308.13) reflects hepatotoxicity profile at performance dosing beyond prescription 2.5-10 mg Oxandrin.​

25 mg strength represents 2.5-10× pharmaceutical while maintaining C17α-methylation preventing first-pass metabolism. WADA S1a prohibited globally.

Product Specifications

Quality Control & Testing Standards

25 mg oxandrolone requires USP potency assay (90-110% HPLC), dissolution profiling, and uniformity verification bridging pharmaceutical and performance standards. Hutech batch documentation confirms C19H30O3 identity and Schedule III-compliant excipients.​

100-tablet institutional bottling prevents diversion matching DEA pharmacy protocols; domestic stability maintains product integrity.

Intended Use & Market Positioning

Serves CIII-licensed institutional researchers managing intermediate-dosage DEA Schedule III inventories. 25 mg/100-tab excludes crossover within premium domestic catalogs. No protocols represented.

Legal & Regulatory Disclaimer

Oxandrolone constitutes DEA Schedule III under 21 USC §812; non-medical handling violates Controlled Substances Act. Buyer assumes Form 222 compliance; zero medical claims provided.